Zydus Cadila gets USFDA Fast Track Designation for Saroglitazar

Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease - primary biliary cholangitis (PBC).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news